A Randomized Controlled Trial of the Efficacy and Safety of Lisdexamfetamine Dimesylate as Augmentation Therapy in Adults With Residual Symptoms of Major Depressive Disorder After Treatment With Escitalopram
The DOI matches its Crossref record.
Abstract
OBJECTIVE: Evaluate the efficacy and safety of lisdexamfetamine dimesylate augmentation for major depressive disorder (MDD) in escitalopram nonremitters. METHOD: In this proof-of-concept study (conducted from July 2009-August 2010) with a prespecified critical α = .10, adults with nonpsychotic MDD (DSM-IV-TR criteria) and residual depressive symptoms (17-item Hamilton Depression Rating Scale score ≥ 4) after 8 weeks of open-label escitalopram were randomized to 6 weeks of lisdexamfetamine dimesylate (20-50 mg/d) or placebo augmentation. The primary endpoint, Montgomery-Asberg Depression Rating Scale (MADRS) total score change in escitalopram nonremitters (MADRS total score > 10) from week 8 (augmentation baseline) to week 14/end of study, was assessed using analysis of covariance, with last observation carried forward. RESULTS: For nonremitters (placebo, n = 64; lisdexamfetamine dimesylate, n = 65), the least squares (LS) mean (90% CI) treatment difference for MADRS total score reduction at week 14/end of study (-2.3 [-4.5 to -0.1]; P = .0902) met the prespecified criterion for lisdexamfetamine dimesylate superiority (adjusted effect size, -0.3); the number needed to treat for MADRS remission (MADRS total score ≤ 10) was 6.7. The LS mean treatment difference in remitters was not statistically significant (1.2 [-1.6 to 4.0]; P = .4726). Among randomized participants, 49.4% (42/85) receiving placebo and 60.2% (53/88) receiving lisdexamfetamine dimesylate had ≥ 1 treatment-emergent adverse event, the most frequent with lisdexamfetamine dimesylate being dry mouth and headache (both 11.4%). Mean (SD) vital sign and electrocardiogram changes (placebo vs lisdexamfetamine dimesylate) were 0.5 (8.98) versus 2.3 (9.04) mm Hg (systolic blood pressure), -1.0 (7.19) versus 0.9 (6.61) mm Hg (diastolic blood pressure), -0.4 (7.39) versus 4.8 (8.64) beats per minute (heart rate), and -1.6 (11.23) versus -4.9 (11.84) milliseconds (Fridericia-adjusted QTc). CONCLUSIONS: Lisdexamfetamine dimesylate augmentation reduced depressive symptoms in participants with inadequate escitalopram response. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00905424.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The safety profile was similar to that observed in studies of LDX in adults with ADHD (Weisler et al, 2009;Wigal et al, 2010) and MDD (Trivedi et al, 2013) and was consistent with those of other long-acting stimulants (Medori et al, 2008;Reimherr et al, 2007).”
From Lisdexamfetamine Dimesylate Augmentation in Adults With Persistent Executive Dysfunction After Partial or Full Remission of Major Depressive Disorder (2014) · cites this paper as Trivedi et al, 2013
In the citing paper
“There has been equivocal evidence for the efficacy of lisdexamfetamine dimesylate augmentation therapy in adults with MDD, with phase 2 studies reporting positive effects on residual depressive symptoms [137] and/or symptoms of executive dysfunction [138] but this was not replicated in phase 3 studies [139].”
From Adult ADHD and comorbid disorders: clinical implications of a dimensional approach (2017) · cites this paper as [137]
In the citing paper
“In one study, LDX augmentation of escitalopram met signal-detection criteria (prespecified 2-sided significance level α¼0.10) for significant reduction in mean Montgomery-Åsberg Depression Rating Scale (MADRS) total score versus placebo in escitalopram nonremitters (Trivedi et al., 2013).”
In the citing paper
“These findings do not support previously published findings of LDX augmentation for MDD based on 2 small phase 2 studies (Madhoo et al., 2014;Trivedi et al., 2013)”
In the citing paper
“The efficacy of LDX in MDD has been investigated in small, phase 2, randomized, double-blind, placebo-controlled studies in individuals with MDD who exhibited inadequate response to antidepressant monotherapy (Madhoo et al., 2014;Trivedi et al., 2013).”
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Still being checked.
Cited by
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Adult ADHD and comorbid disorders: clinical implications of a dimensional approach
Katzman, M. A., Bilkey, T. S., Chokka, P. R., Fallu, A., & Klassen, L. J. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1463-3 · Cited by 732
“There has been equivocal evidence for the efficacy of lisdexamfetamine dimesylate augmentation therapy in adults with MDD, with phase 2 studies reporting positive effects on residual depressive symptoms [137] and/or symptoms of executive dysfunction [138] but this was not replicated in phase 3 studies [139].”
BackgroundLam, R. W., Kennedy, S. H., McIntyre, R. S., & Khullar, A. (2014) · The Canadian Journal of Psychiatry · doi:10.1177/070674371405901206 · Cited by 438
Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach
McIntyre, R. S., Filteau, M.-J., Martin, L., Patry, S., Carvalho, A., Cha, D. S., Barakat, M., & Miguelez, M. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.10.043 · Cited by 421
McElroy, S. L., Hudson, J. I., Mitchell, J. E., Wilfley, D., Ferreira-Cornwell, M. C., Gao, J., Wang, J., Whitaker, T., Jonas, J., & Gasior, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2162 · Cited by 322
Self-citation
Metadata
- Authors
- Trivedi, M. H., Cutler, A. J., Richards, C., Lasser, R., Geibel, B. B., Gao, J., Sambunaris, A., & Patkar, A. A.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Meridien Research (US)
- Duke University (US)
- Corresponding author
- Trivedi, Madhukar H.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2013-08-15
- Volume
- 74
- Issue
- 08
- Pages
- 802-809
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2052168906
- Cited by
- 58
- References
- 0
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 3 · 2023: 3 · 2022: 3 · 2021: 1 · 2020: 3 · 2019: 3 · 2018: 1 · 2017: 7 · 2016: 9 · 2015: 9 · 2014: 8 · 2013: 2
- FWCI
- 6.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- lisdexamfetamine dimesylate, major depressive disorder, residual depressive symptoms, escitalopram, antidepressant augmentation, treatment-emergent adverse events, xerostomia, headache, vital signs, electrocardiographic changes, remission, treatment efficacy and safety, adults with depression, number needed to treat
- MeSH terms
- Lisdexamfetamine Dimesylate, Adolescent, Adult, Central Nervous System Stimulants, Depressive Disorder, Major, Major Depressive Disorder, Dextroamphetamine, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Personality Inventory, Psychometrics, Citalopram, Antidepressive Agents, Second-Generation, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomized Controlled Trial of the Efficacy and Safety of Lisdexamfetamine Dimesylate as Augmentation Therapy in Adults With Residual Symptoms of Major Depressive Disorder After Treatment With Escitalopram. https://app.cochat.ai/papers/10.4088/jcp.13m08360
- The paper
- Trivedi, M. H., Cutler, A. J., Richards, C., Lasser, R., Geibel, B. B., Gao, J., Sambunaris, A., & Patkar, A. A. (2013). A Randomized Controlled Trial of the Efficacy and Safety of Lisdexamfetamine Dimesylate as Augmentation Therapy in Adults With Residual Symptoms of Major Depressive Disorder After Treatment With Escitalopram. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.13m08360
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.